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The  cardiovascular  disease  (CVD)  is  considered  as  a  major  threat  to global  health.  Therefore,  there  is  a
growing  demand  for a range  of  portable,  rapid  and  low  cost  biosensing  devices  for  the  detection  of  CVD.
Biosensors  can  play  an  important  role in the  early  diagnosis  of CVD  without  having  to rely  on hospital
visits  where  expensive  and  time-consuming  laboratory  tests  are  recommended.  Over the  last  decade,
many biosensors  have  been  developed  to detect  a  wide  range  of  cardiac  marker  to  reduce  the  costs  for
healthcare. One  of the  major  challenges  is to find  a  way  of  predicting  the  risk  that an  individual  can
suffer  from  CVD.  There  has been  considerable  interest  in  finding  diagnostic  and  prognostic  biomarkersardiac biomarker
-reactive protein
lectrochemical
ptical biosensor
that  can  be  detected  in  blood  and  predict  CVD  risk.  Of these,  C-reactive  protein  (CRP)  is  the  best  known
biomarker  followed  by cardiac  troponin  I  or T (cTnI/T),  myoglobin,  lipoprotein-associated  phospholipase
A(2),  interlukin-6  (IL-6),  interlukin-1  (IL-1),  low-density  lipoprotein  (LDL),  myeloperoxidase  (MPO)  and
tumor  necrosis  factor  alpha  (TNF-)  has  been  used  to  predict  cardiovascular  events.  This  review  pro-
vides  an overview  of  the  available  biosensor  platforms  for the  detection  of  various  CVD  markers  and
considerations  of  future  prospects  for the  technology  are  addressed.© 2012 Elsevier B.V. All rights reserved.
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Cardiovascular disease (CVD) is a major cause of human death in
both developing and developed countries. According to the World
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ealth Organization (WHO), an estimated 17.5 million (30%) of
ll global deaths in 2005 are associated with CVD and it is esti-
ated that by 2015, CVD can be the leading cause of death in the
eveloping countries [1].  Recently, according to the new European
ardiovascular disease statistics 2008, a staggering figure of over
.3 million deaths in Europe alone and 2 million deaths in European
nion are caused by CVD, and it is overall estimated to cost the EU
conomy D 192 billion a year [2].  The early and quick diagnosis of
ardiovascular disease is extremely important and crucial not for
nly patient survival but also saving cost and great deal of time in
uccessful prognosis of the diseases. Existing methods of diagnosis
or CVD rely heavily on classical methods which are based on tests
onducted in central laboratories that may  take several hours or
ven days from when tests are ordered to when results are received
3]. The diagnosis of CVD has been based on the WHO  criteria,
hereby patients must meet at least two of three conditions: char-
cteristic chest pain, diagnostic electrocardiogram (ECG) changes,
nd elevation of the biochemical markers in their blood samples
3]. Although, ECG is an important management tool for guiding
herapy [4,5], but it is a poor diagnostic test for CVD, because about
alf of the CVD patients who present to the Emergency Department
how normal or no diagnostic electrocardiograms, which makes
arly diagnosis of CVD more difficult [4–7]. Therefore, measure-
ent of cardiac markers is critical in assisting the diagnosis of
VD. A more sensitive and rapid technology platform is therefore
eeded to fulfill the rapid diagnosis requirements in CVD detec-
ion. The elaboration of biosensors is probably one of the most
romising ways to solve some of the problems concerning sensi-
ive, fast and cost effective measurements [8].  Biosensor can help in
apid diagnosis, providing better health care and reducing the wait-
ng time for results dissemination which is highly stressful to the
atients. Recently, lab-on-a chip and microfluidics based biosen-
or technology is reviewed for the detection of cardiac markers [9].
his review provided information on commercially available a few
oint-of-care immunosensing instruments and chip based technol-
gy for the detection of different cardiac biomarkers. In the present
aper, we reviewed the developments in application of biosen-
ors over the past 10 years for the detection of cardiovascular risk
ssessment. This review also summarized the frequently targeted
VD biomarkers in various biosensor platforms and highlighted
he major clinically relevant parameters, such as their detection
imit/range and designing of bioassay.
. Cardiac biomarkers
CVD is not a single disease, but it is a group of different disorders
hat affect heart and blood vessels. CVD includes atherosclerosis
ondition that develops when a plaque builds up in the walls of the
rteries. This plaque narrows the arteries and makes it difficult for
lood to flow through and causes a heart attack or stroke. CVD can
e caused by a range of factors and disorders that include genetic,
ender, age, high blood pressure and cholesterol, diabetes, obesity
nd overweight, smoking and stress. The causes of CVD are more
iverse that clinical testing becomes increasingly complex. There
re a number of diseases associated with CVD that affect different
arts of the body. Although, great progress has been made in the
reatment of this disease, current medical knowledge is unable to
ffectively predict its risk. With regards to predicting CVD risk, one
f the active research areas recently is the use of diagnostic and
rognostic biomarkers that can be identified in blood [10]. On the
asis of diagnostic and prognostic standpoint, CVD biomarkers can
e categorized into pathogenetic and therapeutic types. The diag-
ostic and prognostic biomarkers also provide therapeutic value
n medical applications. The vascular wall releases molecules into
he bloodstream that can reflect the pathological processes takingFig. 1. Most frequently studied biomarkers in relation to the different mechanism
involved in CVD risk [10].
place. In theory, the concentrations of the molecules involved in
different pathological processes could be the biomarkers. However,
not all of these molecules are suited to this aim but should fulfill
certain conditions [10].
There are several important characteristics that an ideal cardiac
biomarker should exhibit. These include: (a) high clinical sensitivity
and specificity, (b) quick release of biomarker in the blood enabling
early diagnosis, (c) capability to remain elevated for longer time in
the blood, and (d) ability to be assayed quantitatively [10]. It is diffi-
cult to select a specific marker for the diagnosis of CVD. Therefore, a
range of biomarkers can potentially be analyzed simultaneously for
the accurate disease diagnosis [6,7,10–13].  Anderson et al. reported
a set of 177 candidate biomarkers that are potential plasma mark-
ers for CVD and stroke [13]. Recently, the most frequently studied
biomarkers are summarized in relation to the different mechanisms
involved in development and rupture of atherosclerotic plaque,
such as endothelial dysfunction, inflammation, oxidative stress,
proteolysis, and thrombosis (Fig. 1) [10].
Several other cardiac-specific biomarkers have emerged as
strong and reliable risk predictors for coronary heart disease, as
listed in Table 1. Of which, CRP has been the most frequently used
single biomarker for cardiovascular risk (CVR). The CVR defined by
the American Heart Association (AHA) and the Center for Disease
Control and Prevention (CDC) is regarded as low risk for a CRP con-
centration below 1.0 mg  L−1, moderate for 1.0–3.0 mg L−1, and high
risk for concentrations over 3.0 mg  L−1 [14]. CRP can rise as high as
1000-fold because of inflammation induced by infection or injury,
often leading to CVR [15]. Recent research suggests that patients
with elevated basal levels of CRP are at an increased risk of diabetes
and hypertension as well as CVD [15].
Myoglobin, although not a very specific marker, but it is the first
marker released after the damage occurred to myocardial muscle
cells. B-type natriuretic peptide (BNP), cardiac troponin I (cTnI),
and CRP are released after myoglobin, but they are specific markers
for coronary events. BNP is useful for the emergency diagnosis of
heart failure and for the prognosis in patients with acute coronary
syndromes (ACS) [16]. CRP is an important prognostic indicator of
CVR and ACS. cTnI has become a standard marker for the detection
64
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Table 1
A summary of primary clinically utilized cardiac biomarkers, highlighting their respective cut-off values.
Cardiac biomarker Type of cardiovascular diseases
involved
Cut-off levels Specificity (low,
medium, high)
MW
(kDa)
Initial
elevation
Time to
peak
Return to
normal
POC test
available
Troponin I (cTnI) Detection of acute myocardial
infarction (AMI)
0.01–0.1 ng mL−1 High 23.5 4–6 h 12–24 h 6–8 days Yes
Troponin  T (cTnT) Detection of AMI  0.05–0.1 ng mL−1 High 37 4–6 h 12–24 h 7–10 days Yes
Myoglobin  Early detection of AMI  70–200 ng mL−1 Low 18 1–3 h 6–12 h 24–48 days Yes
C-reactive  protein (CRP) Early detection of
inflammation/cardiac risk
factor
<103 ng mL−1 low risk
1–3 ×103 ng mL−1 intermediate risk
>3–15 × 103 ng mL−1 high risk (no definitive)
High 125 ND ND ND Yes
Creatine  kinase MB  subform
(CK-MB)
Early detection of AMI  10 ng mL−1 Medium 85 4–6 h 12–24 h 3–4 days Yes
B-type  natriuretic peptide
(BNP)
Acute coronary
syndromes/diagnosis of heart
failure/ventricular overload
High 3.4 ND ND ND Yes
N-terminal pro-B-type
natriuretic peptide
(NT-proBNP)
Acute coronary
syndromes/diagnosis of heart
failure/ventricular overload
0.25–2 ng mL−1 High 8.5 ND ND ND Yes
Myeloperoxidase (MPO) Detection of inflammation Patients with elevated MPO levels
>350 ng mL−1 stratification risk
Medium 150 ND ND ND Yes
Heart  fatty acid binding
protein (H-FABP)
Myocardial necrosis Patients with elevated H-FABP levels elevated
≥6 ng mL−1 stratification risk
Low 15 2–3 h 8–10 h 18–30 h Yes
TNF-  Inflammation/cardiac risk
factor
<0.0036 ng mL−1 low risk
≥0.0036 ng mL−1 high risk
ND ND ND ND ND ND
Interlukin-6 (IL-6) Inflammation/cardiac risk
factor
Low < 0.0013 ng mL−1
Mid  0.00138–0.002 ng mL−1
High > 0.002 ng mL−1
ND ND ND ND ND ND
Fibrinogen  Low < 3.58 × 106 ng mL−1
Mid  3.58–4.20 × 106 ng mL−1
High > 4.20 ×106 ng mL−1
ND ND ND ND ND ND
Source:  Adapted from Refs. [9,11,54,88–92].
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Table 2
Cardiac markers detection on different transduction platforms and their detection range reported in the literature. The time required for the detection of cardiac markers using the methods listed in table is estimated to be within
∼20  min  to 1 h.
Target/biomarker Transduction platform Detection range Assay type Reference
Optical biosensors
CRP
Myoglobin
cTnI
Fluorescence CRP-LOD – 30 ng mL−1 Microfluidic
with
multianalyte
[22]
NF-,  IL-8, IL-6, IL-4, IL-2, IL-2, IL-1b,
IL-12, IL-10, interferon-gamma
(IFN-)
Fluorescence All cytokine 0.01–10 ng mL−1
LOD – 0.01 ng mL−1
Multianalyte [23]
IL-6 Fluorescence using labeled nanoparticles 0.02–1.25 ng mL−1
LOD – 0.007 ng mL−1
Single analyte [24]
TNF- Fluorescence 1 ng mL−1 Single analyte [25]
TNF- Fluorescence 1–0.0016 ng mL−1 Single analyte [93]
CRP Fluorescence 0.1 ng mL−1 Single analyte [26]
CRP Fluorescence 10–105 ng mL−1 Single analyte [27]
CRP Fluorescence 20 ng mL−1 Single analyte [28]
cTnI Fluorescence 0.1–100 ng mL−1 Single analyte [29]
Heart-type fatty-acid binding protein
(H-FABP)
CRP
ELISA H-FABP-LOD < 6 ×103 mL−1
CRP-LOD < 103 ng mL−1
Multianalyte [30]
cTnT ELISA 0.1–100 ng mL−1
LOD – 0.027 ng mL−1
Single analyte [31]
Myoglobin ELISA 20–230 ng mL−1
LOD – 16 ng mL−1
Single analyte [32]
cTnI ELISA Rat troponin I protein (5.3 ×104 to 5.3 × 106 ng mL−1) or human
troponin I protein (4.3 ×104 to 4.3 ×106 ng mL−1)
Single analyte [33]
CRP  and IL-6 Fluorescence/colorimetric 1–1000 ng mL−1
LOD-CRP – 1 ng mL−1
Microfluidic
with
multianalyte
[35]
Myoglobin, creatine kinase mb  (CKmb),
cTnI, and fatty acid-binding protein
(FABP)
Chemiluminescence Myoglobin – 1.2 ng mL−1
CKmb – 0.6 ng mL−1
TnI – 5.6 ng mL−1 and
FABP – 4 ng mL−1
Multianalyte [37]
CRP Chemiluminescence 50–5 ×104 ng mL−1
LOD – 12.5 ng mL−1
Multianalyte [34]
CRP Chemiluminescence 10 to 104 ng mL−1 Microfluidic
with Single
analyte
[14]
cTnI  Colorimetric; PDMS–gold nanoparticle composite film 104 to 5 × 103 ng mL−1 Single analyte [36]
Low-density lipoprotein (LDL) Electrochemiluminescence 0.025–16 ng mL−1
LOD – 0.006 ng mL−1
Single analyte [38]
cTnI  Electrochemiluminescence 0.002 ng mL−1 Single analyte [39]
Metalloproteinase (MMP)-2 SPR LOD – 0.036 ng mL−1 Single [42]
CRP SPR LOD  – 103 ng mL−1 Single marker [43]
B-type  natriuretic peptide (BNP) SPR 5 pg mL−1 to 100 ng mL−1
LOD – 0.005 ng mL−1
Microfluidic
with single
analyte
[48]
CRP  SPR 2–5 × 103 ng mL−1
LOD – 103 ng mL−1
single analyte [44]
CRP SPR 1  ng mL−1 to 5 ×104 ng mL−1
LOD – 1 ng mL−1
Single analyte [45]
cTnT  SPR 0.03 up to 6.5 ng mL−1
LOD – 0.01 ng mL−1
Single analyte [49]
cTnT SPR 0.05  and 4.5 ng mL−1
LOD – 0.05 ng mL−1
Single analyte [50]
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Table 2 (Continued)
Target/biomarker Transduction platform Detection range Assay type Reference
Myoglobin and cTnTI SPR LOD – below 1 ng mL−1 Multianalyte [52]
CRP  SPR 104 ng L−1 Single analyte [46]
TNF-  SPR 1–2 × 103 ng mL−1 Single analyte [53]
CRP  SPR 0.1–200 ng mL−1 Single analyte [47]
cTnT  SPR 100 ng mL−1 Single analyte [51]
cTnT  SPR 0.068 ng mL−1 Single analyte [18]
Myeloperoxidase (MPO) SPR 50 ng mL−1 Single analyte [54]
BNP,  cTnI, myoglobin, and CRP Optical fiber BNP – 0.1 ng mL−1
I cTnI – 7 × 10−3 ng mL−1
MG – 70 ng mL−1
CRP – 700 ng mL−1
Multianalyte [16]
CRP  Optical fiber 5–12.5 × 103 ng mL−1 Single analyte [55]
Nerve  growth factor (NGF) Optical fiber 1–200 ng mL−1 Single analyte [57]
IL-6  Optical fiber LOD – 0.12 ng mL−1 Single analyte [58]
CRP  Optical fiber/fluorescence/evanescent 4.4 × 10−11 to 2.9 × 10−9 ng mL−1 and 1.3 × 10−10 to
2.29 × 10−8 ng mL−1
Single analyte [56]
CRP  Photonic microring resonator 3 × 10−6 ng mL−1 Single analyte [59]
IL-6  Photonic crystal resonant 0.001–0.01 ng mL−1 Multianalyte [60]
cTnT Optomagnetic 0.0039–3.9 ng mL−1 (1–1000 pM)
LOD – 0.0117 ng mL−1
Multianalyte [61]
cTnT  Optomagnetic 0.03 ng mL−1 Single analyte [62]
IL-6  Surface acoustic wave 20 ng mL−1 to 2 × 103 ng mL−1 Single analyte [19,20]
CRP Resonant acoustic profiling 0–231 ng mL−1
Direct assay – LOD 20 ng mL−1
Sandwich assay – 3 ng mL−1
Single analyte [63]
Electrochemical biosensors
Myoglobin Faradaic, Impedance/interdigitated electrodes 100 ng mL−1 Single analyte [64]
CRP  Faradaic, CNT modified carbon electrodes 0.5–500 ng mL−1
LOD – 0.5 ng mL−1
Single analyte [65]
CRP  Faradaic, impedance/gold electrodes to 20 ng mL−1
LOD – 0.1 ng mL−1
Single analyte [66]
Lipoprotein-associated phospholipase
A(2)
Faradaic, iridium-modified carbon electrodes 0–150 U mL−1 Single analyte [72]
IL-6  Faradaic, gold electrodes LOD – 4.1 × 10−3 ng mL−1 Microfluidic
with single
analyte
[94]
Low-density lipoprotein (LDL) Faradaic, impedance/AuNPs-AgCl@PANI-modified glassy carbon
electrode
LOD – 3.4 × 10−3 ng mL−1 Single analyte [73]
CRP Faradaic, magnetic beads with carbon electrodes LOD – 5.4 × 10−11 ng mL−1 Single analyte [67]
cTnT  Non-Faradaic, impedance/Al interdigitated electrodes 0.07–6.83 ng mL−1 Multianalyte [81]
CRP  Faradaic, impedance/gold electrodes 1.15 × 10−13 to 1.15 ng mL−1
LOD – 6 × 10−14 ng mL−1
Single analyte [68]
CRP  Faradaic, diamond like carbon electrodes LOD – 10−4 ng mL−1 Single analyte [69]
IL-6  Faradaic, gold interdigitated electrodes LOD – 0.005 ng mL−1 Single analyte [95]
CRP  Non-Faradaic, gold interdigitated electrodes 25–800 ng mL−1 Single analyte [70]
CRP  and MPO Faradaic, Impedance/iridium oxide modified electrodes LOD-CRP – 1 ng mL−1 and LOD-MPO – 0.5 ng mL−1 Multianalyte [71]
cTnI  and CRP Faradaic, poly(dimethylsiloxane)–gold nanoparticle composite
microreactors
cTnI – 0.01 ng mL−1 and CRP – 0.5 ng mL−1 Microfluidic
with single
analyte
[74]
Cardiac  biomarker N-terminal
pro-B-type natriuretic peptide
(NT-proBNP)
Faradaic, nanostructural gold and carbon nanotubes composite 0.006 ng mL−1 Single analyte [96]
CRP  Non-Faradaic, impedance/Al interdigitated electrodes 0.1 ng mL−1 Single analyte [82]
cTnT  Faradaic, streptavidin-microsphere modified screen printed
electrodes
0.2 ng mL−1 Single analyte [97]
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of acute myocardial infarction (AMI). During the heart infarction,
the troponin T (TnT) is immediately released to the bloodstream,
a biosensor able to monitor this biomarker in a short time could
improve patient care by allowing a definite diagnosis of myocardial
infarction in real time.
Elevated concentrations of these cardiac markers in serum are
associated with recurrent CVD events and higher death rates.
Simultaneous quantification of these biomarkers allows clinicians
to diagnose CVD quickly and/or to accurately design a patient care
strategy. A fast and reliable detection of these proteins will also help
medical professionals differentiate diseases among those show-
ing similar symptoms. The clinically significant sensing ranges of
myoglobin, BNP, cTnI, and CRP are extremely low (pM to nM), and
therefore, assay methods for these biomarkers need to be highly
sensitive. In recent years, different biosensor platforms have been
designed for detection of available cardiac disease biomarkers.
Here, we summarized the most prominently used cardiac biomark-
ers and their detection by different biosensor platforms.
3. Biosensors for CVDs
A biosensor is a device designed to detect and quantify target
molecules that is widely used as a powerful analytical tool in med-
ical diagnostics [8]. It includes proteins detection, nucleic acids or
monitoring antigen–antibody interaction. In principle, it is gen-
erally fabricated by immobilizing a biological receptor material,
for instance, antibody, DNA, or RNA on the surface of a suitable
transducer that converts the biochemical signal into quantifiable
electronic signals. A range of sensors has been developed for CVD
markers detection. Here, a summary of available different sensor
platforms for the detection of CVD and most prominently used
CVD markers is presented and summarized in Tables 1 and 2).
This signal can be electrochemical, optical, mass change (piezo-
electric/acoustic wave) or magnetic in nature [17–20].
3.1. Optical biosensors
Optical biosensors are considered as the most sensitive tech-
niques that are based on the change in the phase, amplitude,
polarization, or frequency of the input light in response to the
biorecognition processes. Optical biosensor can be classified in to
following categories, such as colorimetric, fluorescence, lumines-
cence, surface plasma resonance (SPR) and fiber optics/bio-optrode
based biosensors. In colorimetric and fluorescence-based detec-
tion, either target or biorecognition molecule is labeled with
chromogenic/fluorescent tag, such as dyes. The change in the inten-
sity of the color/fluorescence signal indicates the presence of the
target molecules, which is extremely sensitive, with the detection
limit down to a single molecule [21]. In label-free detection meth-
ods, the target molecules are not labeled, and are detected in their
native forms. This type of detection is relatively easy and cheap
to perform that also allows quantitative/kinetic measurement of
molecular interactions by surface plasma resonance or optical fiber
biosensors [reviewed in 21].  Although, optical biosensors are highly
sensitive, they are bulky, expensive and require dedicated person-
nel to perform the tests. Additionally, colorimetric, fluorescence
and luminometric type of sensors require difficult labeling proce-
dures that depend on indirect indicator based signal schemes.
3.1.1. Fluorescence based biosensors for cardiac markers
detection
A range of different cardiac biomarkers has been detected on
different optical based biosensor platforms. Current research has
more focused on the methodologies for multi-analyte detection
and the integration of immunosensors into chip based microflu-
idic platforms. For example, a self-regulating microfluidic networks
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ased immunosensor is designed for the multianalyte cardiac
arker detection that includes CRP, Mb  and cTnI [22]. Fluores-
ence microsphere immunoarray based platform was employed
sing antibody sandwich assay for the detection of cytokines such
s, TNF-, IL-1, IL-6, and IL-8 [23]. In such type of multi-analyte
etection platform, simultaneous detection of multiple markers,
he rapid availability of results and the simplicity of the experimen-
al setup makes this approach an option for point-of-care testing
evices. A novel sandwich fluoroimmunoassay for IL-6 detection
ith functionalized Rubpy-encapsulated fluorescent core–shell sil-
ca nanoparticles labels has been developed [24]. Here, IL-6 was
easured based on the specific interaction between captured IL-6
ntigens and functionalized fluorescent core–shell nanoparticles-
abeled anti-IL-6 antibodies. The reported method offered potential
dvantages of sensitivity, simplicity and reproducibility for the
etermination of IL-6 in serum samples. In another approach, a 20-
old enhancement of emitted light by fluorescent molecules was
chieved by employing photonic crystals coupled with colloidal
uantum dot emitters that resulted in high signal-to-noise ratio for
ardiac marker (TNF-)  detection [25]. Improvements in photonic
rystal performance can be made to further lower the detection
imits that is useful in detecting new biomarkers associated with
he disease. While Jung et al. developed a competition-based tagged
nternal standard assay to sensitively measure the sub-nanogram
evels of CRP in human serum [26].
In another approach, onchip sandwich assay for the detection
f CRP, which is similar to microarrays using fluorescent tags is
eported [27]. This method was superior in terms of CRP mea-
uring range, but lower in data reproducibility compared to other
ethods. A relatively new method without employing antibody for
he estimation of CRP in serum was developed [28]. This method
entered on the variation of fluorescence intensity of copoly-
ers, containing a fluorophore (Fluoreseinamine isomer 1) and a
RP ligand, O-phosphorylethanolamine (PEA). Here, the copolymer
ontaining fluorophore quenches the fluorescence in the pres-
nce of PEA that eventually determines the CRP levels. Further,
n antibody-tagged fluoro-microbead guiding chip integrated with
icrochannels for simultaneously five identical tests was  devel-
ped for the detection of cTnI in human plasma [29]. Design, picture
nd schematic diagram of the sandwich assay on fluoro-microbeads
uiding chip is shown in Fig. 2. This chip contained five gold
unctional surfaces to perform five identical tests simultaneously
hrough cTnI antibody-linked fluoro-microbeads as the detection
omponent (Fig. 2c: System 1). To amplify the antigen–antibody
inding signal, the avidin–biotin affinity interaction was employed.
fter immobilization of the capture antibody and binding of the
arget antigen cTnI, biotin-conjugated cTnI detection antibody
as loaded into the chip and reacted for 30 min. After washing
he micro-channels with PBS, 0.005% avidin-conjugated fluoro-
icrobeads were injected (Fig. 2c: System 2). Then the amplified
ignal from the avidin–biotin reaction was detected under a flu-
rescence microscope. Human plasma samples were spiked with
arying concentration of cTnI for testing in the Systems 1 and 2
or sensitively detecting cTnI in complex mixtures (Fig. 2c). How-
ver, addition of microfluidic components can minimize procedural
teps such as sample preparations.
.1.2. Luminescence and colorimetric methods for cardiac marker
etection
Recently, luminescence based biosensing platforms and meth-
ds were examined for the early cardiac biomarker detection
14,30–35].  The luminescence methods are broadly classified into
wo types, namely chemiluminescence and electroluminescence. In
hemiluminescence, luminescent signal is generated by the action
f an enzymatic antibody label in the presence of luminogenic sub-
trate while in the case of electroluminescence; the luminescenttors B 171– 172 (2012) 62– 76
signal is induced following an electron transfer reaction of a lumi-
nescent compound immobilized near the proximity of an electrode
surface.
A cardiac chip was developed by exploiting a geometry that
allows for isolation and entrapment of single polymeric spheres
in micro-machined pits, while providing to each bead the rapid
introduction of a series of reagents/washes through microfluidic
structures. Optical signals derived from single beads are used to
complete immunological tests for the simultaneous detection of
the cardiac risk factors, such as C-reactive protein and interleukin-
6 (IL6) in human serum samples [30]. In another approach, PDMS
surface was directly modified with a randomly oriented protein
antibody spots during the polymerization [31] relies on the ability
of the PDMS polymer to entrap macromolecules at its surface while
the polymerization process occurs. This method was employed
to develop a sensitive sandwich immunoassay for CRP detection.
The main advantage of this concept is to be able to combine
both the macromolecule immobilization, without the need of addi-
tional chemicals, and the easy 3D structured platform for sandwich
assays. CRP measurements were also performed by using an inte-
grated microfluidic chip incorporated with magnetic beads [14].
The magnetic beads coated with CRP-specific DNA aptamers rec-
ognize, purify and enrich the target CRP from the sample that
was  sandwiched by binding with acridinium ester-labeled CRP-
antibody for chemiluminescence signal. The development of this
microfluidic system is promising for fast, accurate, and sensitive
detection of CRP.
Currently, electroluminescence (ECL) and colorimetric biosens-
ing platforms have been less extensively examined by researchers
for cardiac markers detections [34,35]. Based on the ECL of CdS
nanocrystals, a novel label-free ECL biosensor for the detection of
low-density lipoprotein (LDL) has been developed by using self-
assembly and gold nanoparticle amplification techniques [34]. The
LDL concentration was  measured through the decrease in ECL
intensity resulting from the specific binding of LDL to apoB-100
(ligand of LDL receptor). The ECL peak intensity of the biosen-
sor decreased linearly with LDL concentration in the range of
0.025–16 ng mL−1 with a detection limit of 0.006 ng mL−1.
Colorimetric method using poly(dimethylsiloxane)
(PDMS)–gold nanoparticles (AuNPs) composite film as basis
with silver enhancement has been reported for the detection of
cardiac troponin I (cTnI) [30,32]. In this study PDMS material was
used because its advantages. Firstly, the polymer matrix of PDMS
could protect AuNPs from aggregation, so this PDMS–AuNPs com-
posite film could be well stored at 4 ◦C for several months which
enhanced the stability and prolong shelf-life of the device. Exper-
imental procedure for silver enhancement colorimetric detection
of cardiac troponin I, is shown in Fig. 3. For cTnI detection, the
monoclonal antibody against cTnI was firstly immobilized on the
PDMS–AuNPs composite film, followed by blocking solution and
cTnI under the procedure as shown in Fig. 3. The mechanism of
gold basis silver enhancement method is that AuNPs play a role
of catalyst during reactions of silver reduction, and this catalytic
ability could be inhibited when there were proteins covering the
surface of AuNPs, which influence the amount of reduction silver
metal, which led to the color difference in the reaction mixture.
This inhibition effect could be distinct due to different species,
quality and/or quantity of covering proteins. The results were
consistent with that from Enzyme-linked immunosorbent assay
(ELISA), which is considered to be one of the most sensitive and
standard techniques [30].3.1.3. ELISA based methods for cardiac marker detection
ELISA typically relies on optical properties of chromogenic
reporters to give rise to a sensitive signal into either colorimet-
ric, fluorogenic or luminescent forms, respectively. ELISA has been
A. Qureshi et al. / Sensors and Actuators B 171– 172 (2012) 62– 76 69
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idely utilized for the detection of cardiac markers [36–39].  Darain
t al. reported a simple and highly efficient sandwich ELISA in
hich in-channel polystyrene was immobilized with antibodies,
nd fabricated plastic based microfluidic chip for the detection of
yoglobin [38]. Cardiac multianalytes, such as heart-type fatty-
cid binding protein (H-FABP) and C-reactive protein (CRP) were
etected in a simple, rapid and “digital-style” semi quantitative
ateral flow assay using an in-house ELISA [36]. This assay was
ble to simultaneously detect cardiac markers and enables pre-
icting early CVD risk, simply by counting the number of red lines
n the test without any expensive reading instruments. Cho et al.
eported a chemiluminometric biosensor system for point-of-care
esting using an immuno-chromatographic assay combined with
n enzyme (e.g., horseradish peroxidase) tracer, which produces
 light signal measurable on a simple detector [37]. In this work,
o enhance the sensitivity, biotin–streptavidin capture technology
as employed in preparing an immuno-strip that was  then inte-
rated onto the chip in order to generate the ELISA-on-a-chip (EOC)
iosensor, and sensitively detected cTnI as low as 0.027 ng mL−1
etection limit. However, further miniaturization of sensor plat-
orm has to be provided without sacrificing the detection capability.
A relatively different method involving specific peptide
equence of cardiac marker detection has been reported. This
ethod utilizes polyvalent phage display to isolate unique linear
eptide motifs which recognize both the human and rat homologs
f troponin I [39]. The peptide specific for human troponin I has a
equence of FYSHSFHENWPS, while FHSSWPVNGSTI for the rat tro-
onin I that later detected by ELISA. It was shown that the binding
ffinities of the phage displayed peptides were decreased by the
resence of complex tissue culture media, and the addition of 10%
alf serum further interfered with the binding of the target proteins.dwich immunoassay on the fluoro-microbeads guiding chip [29].
In this study, kinetic indirect phage ELISAs revealed that both tro-
ponin I binding peptides were found to have nanomolar affinities
for the troponin proteins while attached to the phage particles [31].
These new peptides may  have potential utility in the development
of new clinical assays for cardiac injury as well as in monitoring of
cardiac cells grown in culture.
3.1.4. SPR based biosensor for cardiac marker detection
Surface plasmon resonance (SPR) is a unique optical transduc-
tion method, which has been commercially employed for optical
biosensors [40]. SPR biosensors exploit special electromagnetic
waves – surface plasmon to probe changes in the refractive index
(RI) at surfaces of metals. SPR biosensors can therefore be used to
monitor the interaction between an analyte and its biospecific ele-
ment immobilized on the metal surface without the use of labels.
The basic SPR apparatus is referred to as the Kretschman prism
arrangement [40].
In the SPR, a thin film of metal (usually a 400–500 A˚ thick
gold or silver film) is coated on the prism onto which a biosens-
ing layer is coated by immobilization of biorecognition elements
(proteins/antibodies/DNA/RNA). When an incident light of an
appropriate wavelength strikes on the dielectric–metal interface
at a particular angle, it induces SPR phenomenon at the metal sur-
face. Depending upon the thickness of a molecular layer at the
metal surface, SPR results in a graded reduction in the intensity
of the reflected light [41]. Thus, one can observe a sharp minimum
of light reflectance when the angle of incidence is at this proper
resonant angle. Since the resonance angle depends on several fac-
tors (e.g., the wavelength of the incident light, the metal, and the
nature of the media in contact with the surface) the nature of the
media can be sensed by measuring this resonance angle. Further,
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n addition to the prism coupling, SPR sensors can also be based on
ptical fibers or integrated optical waveguides. Biomedical appli-
ations take advantage of the exquisite sensitivity of SPR to the RI
f the medium next to the metal surface, which make it possible
o measure accurately the capturing of target biomarkers on the
etal surface [41].
SPR based sensing platforms have been extensively studied and
pplied for the detection of cardiac makers that include metallo-
roteinase (MMP)-2 [42], CRP [42–47],  B-type natriuretic peptide
BNP) [48], cTnT [49–51],  myoglobin [52], cTnI [18,52],  TNF- [53],
nd MPO  [54]. A one-step SPR based sandwich assay format for
he quantification of MMP-2 has been reported with Biacore 2000,
sing colloidal gold with a particle diameter of about 20 nm for
ignal amplification [42]. The reported assay has a detection limit
elow the level documented by established methods for MMP-2
etection (Table 2). A modified CRP (mCRP) was detected using
PR based sensor because mCRP is regarded as a powerful inducer
han pentamer CRP (pCRP), therefore, mCRP is considered to be
mportant indicator for assessing the risk of developing CVD. Three
onoclonal antibodies (Mabs), C8, 8D8, and 9C9, were immo-
ilized on a protein G layer for subsequent CRP detection. It isoponin I: (a) PDMS chip with HAuCl4 solution, (b) photo of PDMS–AuNPs composite
shown that detecting pCRP using Mab  C8, the SPR bioassay pro-
vided sufficient sensitivity to evaluate whether or not a patient
is at risk of developing CVD [43]. A miniaturized immunosensor
is designed to determine trace levels of cardiac marker, B-type
natriuretic peptide, using a microfluidic device combined with a
portable SPR sensor system that showed a detectable concentration
range 5 pg mL−1 to 100 ng mL−1 by monitoring the SPR angle shift,
which covers the required detection range for the B-type natriuretic
peptide concentrations found in blood [48].
A carboxymethyldextran hydrogel planar sensor chip was
employed for the detection of cTnT [49]. This sensor was coupled
to the SPR AutoLab Spirit® system (Eco Chemie, Netherlands)
attached at the bottom of the prism with cedar oil and a flow
cell was  installed on the chip. In this work, the well-established
biotin–streptavidin chemistry was used to increase the amount
of immobilized antibodies by highly specific interaction between
the biomolecules. Further, two myocardial infarction biomarkers,
myoglobin and cardiac troponin I, were quantified at biological
levels and in undiluted serum without sample pretreatment
using SPR sensors and the detection limits for both markers
were below 1 ng mL−1 [52]. A modified surface chemistry on SPR
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ensor surface for CRP detection is developed in which poly(3-
2-((N-succinimidyl)succinyloxy)ethyl)thiophene) (P3SET), a
oly(thiophene) with pendant NHS ester groups was prepared and
sed for the formation of a self-assembled monolayer (SAM) on a
old surface for CRP biosensor fabrication [46]. Improvements in
he fabrication of SPR sensors have been attempted and demon-
trated the enhancement of sensitivity for an SPR interface using
retschmann’s configuration, through nano-gratings combined
ith nano-patterned immobilization of surface bioreceptors
53]. This configuration resulted in high electromagnetic field
ntensity for the detection of TNF-. In an interesting approach
scherichia coli outer membrane with auto displayed Z-domain
as used as a molecular recognition layer for the detection of CRP
sing SPR biosensor [47]. From this study, the LOD of SPR biosensor
as estimated to improve more than 100-fold compared to the
PR biosensor with the antibody-layer by physical adsorption.
he main problem of SPR sensor could be mainly because of its
ouling ability, low affinity and specificity that affect sensitivity
f biosensing transducers. One study attempted to improve these
actor by utilizing a modified method of SAM formation using a
omogeneous mixture of oligo(ethylene glycol) (OEG)-terminated
lkanethiolate and mercaptohexadecanoic acid (MHDA) on gold
urface for detecting cardiac troponin T [51].
.1.5. SPR based fiber optic biosensors for cardiac marker
etection
Recently, SPR based on optical fibers have been utilized for the
etection of cardiac specific biomarkers BNP [55], cTnI, Mg  [55],
RP [16,55,56],  nerve growth factor (NGF) [57], and IL-6 [58]. The
etection principle of a large class of fiber optic biosensors (FOBs) is
ased on the principle of total internal reflection fluorescence (TIRF)
55,56]. An evanescent wave forms when the light propagates in the
ber core at an incident angle greater than the critical angle, which
esults in total reflection of incident light. This is due to the change
n high to low refractive indices of the media, respectively. The
vanescent wave can be used to excite fluorophores of the immo-
ilized fluorescently labeled species, resulting in the evanescent
ave excitation of fluorescence. The intensity of the evanescent
ave decays exponentially along the direction perpendicular to
he interface (typical penetration depth of 100–200 nm range). This
haracteristic enables real-time monitoring of the kinetics behav-
or between receptors and target analytes during the measurement.
oreover, the detected signal intensity of an FOB depends on the
mount of fluorophores in the captured target molecules, and the
elationship between the signal response and the concentration of
arget molecules can be determined accurately. Studies involving
se of novel FOB has been reported to determine the mCRP-anti-
RP binding kinetics [55]. In this FOB platform the fluorescence
ignal excited by evanescent wave in the near field region of fiber
ore surface and a photomultiplier tube (PMT) facing the fiber wall,
nd perpendicularly to the fiber axis was fixed that enabled to col-
ect the fluorescence signal more efficiently in the FOB. The reported
OB was capable of detecting CRP at physiological concentration.
andwich immunoassay has also been performed using FOB in
hich fiber optic probe was used as a dip probe for the sensitive
etection of IL6 (5 pM or 0.12 ng mL−1) [58].
.1.6. Other optical based biosensors
Refractive index based other optical biosensors have been
eported. These include, resonant biosensor to detect CRP markers
nd silicon photonic mircroring resonators using optofluidic plat-
orm to detect IL-6 [59,60].  Optomagnetic biosensors have been
pplied for the detection of cardiac troponin cTnT and I [61,62].
hile a prototype hand held device was developed actuated mag-
etic nanoparticle labels (500 nm)  bound to the sensor surface
ia a sandwich immunoassay for the optomagnetic detection ofors B 171– 172 (2012) 62– 76 71
cTnT [61]. Optomagnetic detection of cardiac biomarkers using
functionalized magnetic particles has high potential in analytical
performance and ease-of-use that is suitable for applications in
point-of-care diagnosis [61,62].
3.2. Acoustic biosensors for detection of cardiac markers
Acoustic biosensors allow label-free detection of biomolecules
and analysis of binding events mainly for CRP and interleukin fam-
ily of proteins. The detection of these markers is based on the mass
of captured analyte by an immobilized receptor molecule on the
quartz crystal resonator surface, which is proportional to the res-
onant frequency [63]. Their detection has also been demonstrated
by using surface acoustic wave based biosensor platform [19,63].
It was found that ZnO/SiO2/Si Love mode surface acoustic wave
(SAW) biosensor for the detection of interleukin-6 (IL-6) has been
reported with high sensitivity. This sensor consisted of fully inte-
grated CMOS Si chips for portable real time detection of interleukin
family of proteins in human serum [19]. However, performances
of acoustic biosensors depend on factors, such as its temperature
dependence, attenuation and the Raleigh waves are surface-normal
waves, deposition of non-specific molecules, dust or other contam-
inants on sensor crystals may  contribute to large background signal
noises that may  affect sensitivity and specificity of the sensors.
3.3. Electrochemical biosensors
Electrochemical biosensors are affinity based biosensors where
they use an immobilized recognition element (probe) that binds
the target/analyte molecule selectively. The detection of binding
a target to probe in solution is governed by detecting change at a
localized surface in terms of change in currents and/or voltages.
Based on their operating principle, the electrochemical biosen-
sors can employ potentiometric, amperometric and impedimetric
transducers converting the chemical information into a measurable
amperometric signal. Thus, this category excludes sensors which
require light (e.g., surface plasmon resonance or fluorescence),
mechanical motion (e.g., quartz crystal microbalance or resonant
cantilever), or use of magnetic particles. Due to their low cost, low
power and ease of miniaturization, electrochemical biosensors hold
great promise for applications where minimizing size and cost is
crucial, such as point-of-care diagnostics and bio-warfare agent
detection.
The first scientifically proposed and successfully commercial-
ized biosensors were those based on electrochemical sensors for
multiple analytes. Currently, transducers based on semiconduc-
tors and screen printed electrodes represent a typical platform in
electrochemical biosensor for detection of CVR markers. Electro-
chemical biosensors for the detection of cardiac markers, including
cardiac troponin I or T (cTnI/T), myoglobin, CRP, Lipoprotein-
associated phospholipase A, IL-6, LDL and MPO  have been published
in the last few years. Most notably, the detection of myoglobin
was  performed by a miniaturized point-of-care sensor, which was
based on impedimetric sensing of cardiac enzyme captured by an
antibody layer immobilized on a planar gold electrode sensor [64].
Gold/Ti-on-glass substrate has been used on which the working
electrode was  immobilized with antibodies that are in turn inte-
grated with a microfluidic system. The presented biosensor was
able to detect the myoglobin antigen concentration of 100 ng mL−1.
A number of studies on developing electrochemical biosensors for
the detection of CRP have been published in the last few years
[65–71].
A three-dimensional ordered macroporous (3DOM) gold film
modified electrodes have been employed for the development of
electrochemical impedance biosensor for the detection of CRP [66].
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he procedure for preparation of 3DOM gold film electrodes is
hown in Fig. 4.
The electrode used in this sensor was electrochemically fabri-
ated with an inverted opal template that enabled enhanced surface
rea of the 3DOM gold film up to 14.4 times higher compared to
lassical bare flat electrodes. The presented CRP immunosensor
as developed by covalently conjugating CRP antibodies with 3-
ercaptopropionic acid (MPA) on the 3DOM gold film electrode
nd schematic is presented in Fig. 5. The CRP concentration was
easured through the increase of impedance values in the cor-
esponding specific binding of CRP antigen and CRP antibody. This
nhanced sensor surface area of 3DOM gold film after immobilizing
RP antibodies increased the electron-transfer resistance (Ret) val-
es that were proportional to the CRP concentrations in the range
f 0.1–20 ng mL−1. The lowest detection limit here for CRP antigen
as as low as 100 pg mL−1 [66].
A possibility of using a range of dc and ac electrochemical
echniques to probe associative interactions of CRP with CRP
ntibody immobilized on a gold electrode surface was investi-
ated by Hennessey et al. [68]. It was demonstrated that the
nvestigated electrochemical techniques can be used efficiently
o probe these interactions over a wide CRP concentration range,
rom 1.15 × 10−5 to 1.15 mg  L−1. The measured sensitivity of the
echniques was in the following decreasing order: differential
ulse voltammetry, charge-transfer resistance obtained from elec-
rochemical impedance spectroscopy (EIS), cyclic voltammetry,
hronoamperometry, and double-layer capacitance deduced from
IS measurements which gave the poorest sensitivity. The lowest
etection limit of CRP antigen concentration was 6 × 10−6 mg  L−1. A
apacitive biosensor based on chronoamperometry was developed
y using diamond-like carbon (DLC) film as an electric isolat-
ng layer and applicability of the biosensor was demonstrated
y detecting CRP [69]. The lowest detection limit of CRP antigen
oncentration in this method was 0.01 pg mL−1. Centi et al. devel-
ped electrochemical sandwich assay for the detection of CRP [67].
he screen-printed carbon electrodes and magnetic beads were
mployed in this assay to develop electrochemical assay that had a
imit of detection of 0.054 mg  L−1 CRP in serum.n of 3DOM gold film [66].
Electrochemical biosensors based detection offer sensitivity,
selectivity and reliability, making them very attractive tools for
biomarker protein detection. However, these biosensors suffer
from perturbations on the sensor surface that are influenced by
different pH, ionic strength and co-existing molecules in biologi-
cal fluids. The biological recognition elements used in a majority
of electrochemical biosensors are antibodies. The fact that these
antibodies are generated, isolated and purified after the adminis-
tration of a desired antigen in to the animal models making them
inherently trained to function in normal physiological solutions.
This makes antibodies difficult to contain specific binding ability
outside of the physiological environments or synthetic buffers. The
functionality of antibodies may  further decline in presence of exter-
nal redox mediators that are essentially mixed with the sample
solution for electrochemical sensor platforms.
3.3.1. Use of nanomaterials in electrochemical biosensors
Use of nanomaterials in electrochemical biosensors has received
considerable attention by the research groups over the past
decade. The demonstration of novel and unique detection platform
for cardiac marker detection by utilizing nanoparticles, nano-
tubes, nanowires and nanocomposites has been reported. There is
much versatility in the selection of nanomaterials to measure the
detectable signal by which analyte concentrations can be deter-
mined. Recently, a sensitive, disposable, and easy to operate sensor
based on heterogeneous sandwich immunoassay for high sensitiv-
ity CRP (hs-CRP) measurement was  developed [65]. This biosensor
utilized screen-printed electrodes modified with multi-walled car-
bon nanotubes (SPE/CNTs) and protein A to ensure the oriented
immobilization of anti-CRP antibodies and sensitively detected CRP
at 500 pg mL−1 levels. In another study, detection of lipoprotein-
associated phospholipase A2 (Lp-PLA2) is reported in which carbon
paste doped with iridium nano-particles as working electrodes was
used as biosensor [72]. Here, the detection of Lp-PLA2 was  in the
range 0–150 U mL−1 with a sensitivity of 1.45 nA/U. The detection
of low-density lipoprotein (LDL) using silver chloride@polyaniline
(PANI) core–shell nanocomposites (AgCl@PANI) combined with Au
nanoparticles (AuNPs) hybrid material has been reported [73]. The
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ybrid material was used to provide surface for high antibody load-
ng due to its large surface-to-volume ratio. The method was  based
n adsorption of antibody to apolipoprotein B-100 (aopB-100) on
n AuNPs-AgCl@PANI-modified glassy carbon (GC) electrode. The
iosensor exhibited a highly sensitive response to LDL with a detec-
ion limit of 0.34 pg mL−1.
In a study by Zhou et al. developed an electrochemical
mmunoassay for the simultaneous detection of cardiac troponin I
cTnI) and CRP in which CdTe and ZnSe quantum dots were utilized
or sandwich immunoassay. Here, Cd2+ and Zn2+ were detected by
quare-wave anodic stripping voltammetry to enable the quan-
ification of the 2 biomarkers in 20 human serum samples [74].
imilarly, Kunduru et al. designed nanotechnology-based electro-
hemical biosensor using micro- and nano textured polystyrene
olymer structures. The results demonstrated that scaling down
he surface texturing from the micro- to the nano scale enhances
he sensitivity of this detection method for CRP [75]. In the work by
hammad et al., gold nanoparticles have been electrodeposited on
ndium tin oxide (ITO) and applied to detect molecular interaction
etween human cardiac cTnI and specific antibody by measuring
pen circuit potential (OCP). In this work, a new strategy has been
dapted to obtain an electrical signal due to the enzyme-based
mmune catalytic reaction and detected 1–100 ng mL−1 I cTnI [76].
lectrochemical immunosensor based on metal nanoparticles for
ardiac myoglobin detection in human blood plasma has been
eported [77]. In this work, cardiac myoglobin detection was based
n direct electron transfer between the Fe(III)-heme and the elec-
rode surface that was modified with metal nanoparticles (gold,
ilver, and copper) stabilized by didodecyldimethylammonium
romide and antibodies. The method proposed does not require
abeled secondary antibodies that resulted in a detection limit of
 ng mL−1 with a broad range of working concentrations.
The iridium oxide (IrOx) nanowires based electrochemical
iosensor was presented for the detection CRP and MPO  cardio-
ascular disease biomarkers [71]. This biosensor was  based on
lectrical detection of protein biomarkers wherein an immunoas-
ay was built onto the iridium oxide nanowires that in turn
ndergoes specific electrical parameter perturbations during each
inding event associated with the immunoassay. The studynsor fabrication process [67].
demonstrated that the iridium oxide nanowires has an ability to
detect very small changes to the surface charge and this capability is
utilized for achieving the performance metrics and forms the basis
of the key innovations of this technology to improve selectivity and
sensitivity of detection.
3.3.2. Electrochemical biosensors without electron mediators
Another class of electrochemical biosensors that do not utilize
redox mediators known as non-Faradaic electrochemical sensor
has been employed for the cardiac marker detection in buffer and
complex serum greatly varies because of the interference of the
non-specific molecules and ions. Capacitive electrochemical (non-
Faradaic) immunosensor has recently been presented [78] for the
detection of TnT based on the use of immobilized antibodies spe-
cific for TnT. The device was able to detect TnT levels in the range
0.07–6.83 ng mL−1 in human serum from patients with cardiac dis-
eases and in the range 0.01–5 ng mL−1 for TnT in phosphate buffer
saline. In the work by Qureshi et al. [79], gold interdigitated capac-
itor arrays were employed for the development of reagent-less,
label-free capacitive electrochemical biosensors for the detection
of CRP that is based on charge distribution on the surface of capac-
itors. The sensitive detection of CRP capturing on capacitors was
observed in a dynamic range 100–500 pg mL−1 under standard
conditions that includes the defined geometry of electrodes and
specified biochemical assay conditions.
Electrochemical capacitive immunoassays are promising alter-
natives to existing immunochemical tests for the development
of hand-held devices for point-of-care applications. The attrac-
tion of affinity-based capacitive sensors is that they are able to
determine the analyte directly in a sample with no or very lit-
tle sample preparation. The sensing principle of these sensors
is based on changes in dielectric properties, charge distribution,
and/or conductivity change brought on by bioreceptor–target ana-
lyte complexes formed on the surface of the electrodes. Capacitive
affinity biosensors can be constructed by immobilizing recogni-
tion elements on the electrodes, and measuring changes in the
dielectric/surface properties when an analyte binds. It can then be
correlated to the bound target protein molecules and the amount
captured by bioreceptors immobilized on the surface. For providing
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arger sensor surface area, conductors can be made into a pat-
ern of micro to nano-interdigitated fingers. However, non-specific
nd large background signals affect these types of sensors and
educe signal-to-noise ratio and therefore, further improvements
s required for improving these label-free biosensors.
.4. Magnetic biosensors
Magnetic particles/beads have been established in life sciences
nd used for many years in biological assays. A wide variety of
iological species, such as cells, proteins, antibodies, pathogens,
oxins, and DNA can be labeled by attaching them to superpara-
agnetic microbeads. These particles range in size from a few
anometers to a few microns, and the normal magnetic bead struc-
ure consists of many iron oxide (magnetite) crystallites, which
rovide the paramagnetic attraction of the particles to a magnet
nd they are encapsulated in plastic or ceramic spheres. The beads
re coated with a chemical or biological species (e.g., DNA or anti-
odies) that selectively binds to the target analyte. To date, several
uthors described the interaction of magnetic beads with a mag-
etic field and the ensuing visualization of binding effects [80], or
se the beads as a separation and magnetic immobilization plat-
orm [81,82] although magnetic beads/particles based biosensing
latforms have been less extensively examined by researchers for
ardiac markers detections.
A rapid immunoassay system based on antibody-coated
icrometer-sized paramagnetic particle was reported by Luxton
t al. [83] for the detection of cardiac markers including CRP and
reatine kinase isoenzyme MB  fraction (CKMB). This assay do not
equire sample preparation or washing step, and results can be
btained in less than 3 min  after introducing the sample into the
essel with sensitivities in the normal clinical range.
The use of magnetic beads in CRP detection has also been
escribed by other research group [84] where magnetic bead was
sed only for separation of bound and unbound aggregates of
andwich assay. The quantification of magnetic beads for the CRP
etection has also been described by Kriz et al. [85]. In this publi-
ation, the authors describe the sedimentation of magnetic beads
omplexed with silica microparticles upon appearance of CRP in
he sample. The content of magnetic beads in the sedimented
hase of the measurement is then analyzed by a single magnetic
esonant coil. The measurement needs only 11.5 min, but shows
etection limits of 0.2 mg  L−1 and a coefficient of variation (CV)
f 11%. The same research group published a rapid detection sys-
em based on the same technique [86] which provides results after
.5 min  and has a detection limit of 3 mg  L−1 and a CV of 10.5%. In
nother approach, CRP detection was reported by another research
roup [87] where the most significant difference between previ-
usly methods is the measurement head. This reported system uses
wo different excitement coils in a frequency mixing mode. This
nables the very low detection limit of 25 g L−1, accompanied by
he low CV of 4.2%.
A new strategy for the detection of cardiac troponin I that relies
n competitive exchange interactions of an analyte was reported
20]. In this method, use of superparamagnetic beads and of mag-
etic tweezers apparatus allows a small force to be applied to the
ethers, providing a driving force for the competitive exchange
eaction and selectively detected protein in a sensitive reagent-
ess fashion. Although, to obtain the reproducible results from the
evice, further optimization in the fabrication of sensor would be
ecessary for better sensitivity.. Conclusions and perspectives
It is critically important to diagnose CVD at early stages of
ts progression, which allows successful treatment and recoverytors B 171– 172 (2012) 62– 76
of patients. Therefore, it is essential to develop simple and sen-
sitive CVD diagnostic methods that can detect multiple cardiac
biomarkers at very low concentrations in biological fluids. Cur-
rent biosensing platforms can fulfill these demands but require
sophisticated laboratory equipment and training. In this review,
available biosensing platforms for CVD biomarkers detection are
summarized. Most frequently used CVD biomarker/s for biosensing
are in the order of CRP > cTnI > myoglobin > IL-6 > TNF on optical,
electrochemical and magnetic transduction formats. A majority
of cardiac biomarkers are also markers of common inflamma-
tion, making it difficult to distinguish the cardiovascular risk. An
inflammatory process in patients can occur without the existence
of cardiovascular disease, which may  incur a high rate of false-
positives. Therefore, a multiple marker detection strategy needs
to be adapted using a combination of established and new cardiac
markers, which helps in making correct clinical decisions. Future
innovation in biosensor technology can be directed toward (a) iden-
tification of new and non-inflammatory cardiac biomarkers and
their validation, (b) development of novel biorecognition elements
in place of classical antibodies, (c) direct detection of biomark-
ers in biological fluids (blood) without sample preparations, (d)
miniaturization of electronic transducers for portability, and (e)
patterning arrays and microfluidics suitable for multiple biomarker
detection. Combinations of all the above features are essential to
making devices of high potential for early CVD diagnosis with pre-
cision. Improving sensitivity, specificity, and making biosensors a
low-cost and point-of-care capability is another challenge.
In recent years, nanomaterials have shown wide applications in
biosensing. One of the most striking advantages of such nanoma-
terials is to use surface activated magnetic nanoparticles (SAMN).
These SAMN enable functionalization and concentration of tar-
get protein molecules directly from the complex mixtures, such
as blood/serum. Concentration of target protein from the complex
serum can be achieved by magnetic nanoparticles functionalized
with specific affinity ligands (antibodies/aptamers). The magnetic
properties of nanoparticles provide magnetic separation simply by
placing a magnet in close proximity of the suspension, making
them concentrate with captured target proteins. This methodol-
ogy holds great promise in electrochemical chip based biosensing,
mainly for drawing the target captured magnetic nanoparticles on
the sensor surface immobilized with specific affinity ligands. This
method enables washing away the magnetic nanoparticles with no
target while withdrawing the magnet away, and leaving behind
only those that bound to the target proteins for specific detec-
tion and quantification. The concept of using nanomaterials as one
of the candidates to further improve the sensitivity in develop-
ing highly sensitive devices for early diagnosis and point-of-care
applications. Early diagnosis will aid in increase in the human sur-
vival rate that requires precise diagnosis, which is only possible
with multiple biomarker detection for CVD risk. However, appro-
priate investment and funding support mechanisms are needed to
facilitate moving this technology from research to the commercial
applications.
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